Clinical Trial: SVF for Treating Pulmonary Fibrosis Post COVID-19

Study Status: COMPLETED
Recruit Status: COMPLETED

Official Title: The Role of Cellular Therapy With SVF Cells (Stromal Vascular Fraction) of Adipose Tissue Origin in the Treatment of Pulmonary Fibrosis Post COVD-19

Brief Summary:

General description of the study

This is a prospective, multicenter, expanded access interventional study of subjects recovered from COVID-19 pneumonia to assess their response to intravenous administration of adipose-derived autologous SVF.

Primary objective

The purpose of this study was to evaluate the safety of single intravenous injections of autologous adipose-derived SVF produced using the GID SVF-2 device system for the treatment of secondary respiratory distress associated with COVID-19.

Secondary objective

To evaluate the efficacy of the initial treatment with SVF IV.